BioMarin Pharmaceutical Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2021
July 20, 2021
Share
BioMarin Pharmaceutical Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported total net Revenue was $501,693,000 against $429,485,000 a year ago. Income from operations was $11,672,000 against loss from operations of $40,945,000 a year ago. Net income was $12,941,000 against net loss of $29,183,000 a year ago. Basic per share was $0.07 against basic loss per share of $0.16 a year ago. Diluted per share was $0.07 against diluted loss per share of $0.16 a year ago.
For the six months, the company reported total net Revenue was $987,723,000 against $931,554,000 a year ago. Income from operations was $36,758,000 against $64,016,000 a year ago. Net income was $30,312,000 against $52,198,000 a year ago. Basic per share was $0.17 against $0.29 a year ago. Diluted per share was $0.16 against $0.28 a year ago.
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.